Latest Breaking News On - Sahm nasseri - Page 2 : comparemela.com

Share this article Share this article NEW YORK and PERTH, Australia, April 30, 2021 /PRNewswire/  PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced a first quarter update highlighting the progress of its development pipeline, growth of its U.S. operations and upcoming milestones. PYC has had an exciting quarter of progress against our Company objectives. We have achieved continued validation of our PPMO technology in our lead candidate VP-001 for retinitis pigmentosa type 11, further development of our ocular pipeline as well as PYC s first set of preclinical data from our CNS discovery efforts demonstrating superior delivery of RNA therapeutic throughout the brain and spinal cord. The potential of our pioneering PPMO technology is vast and we look forward to advancing this technology to provide solutions for patients with inherited ocular and ne

Western australiaMichael rosenblattPhosphorodiamidate morpholino oligomerKaggen ausmaSahm nasseriLeo vartorellaDeborah elson matthew deyoungGlenn noronhaDrug administrationExecutive officerAlan tribeOcular diseasesInvestigational new drugNervous systemChief development officerChief business officer